A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal and related conditions. It is a striking claim in a field where the difference between a useful nudge and a dangerous false signal matters enormously.
Two Additions, Vastly Different Stakes
H. pylori affects roughly half the world’s population and is tied to peptic ulcer disease and gastric-cancer risk. Many people have no symptoms, which is precisely why wider access to a preliminary signal could have value. Standard confirmation, though, still comes from established routes: a urea breath test, stool antigen test, or endoscopic biopsy. A photograph cannot casually elbow those methods aside, no matter how slick the software may look.
Ebola is an even more sensitive proposition. It is rare, potentially fatal, and can bring severe diarrhea and fluid loss during outbreaks. Faex is exploring whether visual stool patterns might assist preliminary triage where laboratory resources are thin and testing delays hurt public-health response. That is worth researching. But this is not an Ebola test, and the company is explicit that it does not replace RT-PCR laboratory diagnosis, infection-control protocols, or clinical assessment. Frankly, that disclaimer needs to stay in giant letters whenever anyone discusses this feature.
Internal Validation Is a Starting Line, Not the Finish
The part that makes this sector watcher tap the brakes is straightforward: both new indications have been internally validated with Faex’s proprietary datasets, but neither has entered clinical trials. Neither has FDA clearance or approval. More broadly, the company says its 18-condition panel has not been independently replicated or peer reviewed as a complete panel.
That does not mean the work is worthless. It means the work is early. Digital-health outfits routinely discover that a promising internal model has a tougher time when it meets new populations, different phone cameras, variable lighting, real-world user behavior, and clinicians who quite reasonably ask for hard evidence. Stool imagery is especially susceptible to messy collection conditions. A system has to prove it can separate meaningful visual changes from ordinary variation without nudging worried users toward panic or false comfort.
Faex’s framing is more sensible than the usual “AI will replace everything” chest-thumping. Its stated aim is preliminary awareness and professional review, not diagnosis. The platform reviews color, consistency, texture, blood, mucus, and other visible anomalies, while also providing Bristol Stool Form Scale classifications and evaluating seven anomaly categories. Repeated images could potentially create a more useful longitudinal record than one isolated snapshot. That is the core thesis, and it has some practical logic.
Evidence Will Decide Whether This Becomes Useful
The company’s FECAL-AI clinical trial at Hospital Dr. Sótero del Río in Chile is the more concrete item to watch. Investigators are comparing image-derived signals in colorectal-cancer screening with conventional fecal immunochemical testing, or FIT. Separately, Faex is exploring a larger colorectal-cancer screening study involving the United Kingdom’s National Health Service and National Institute for Health and Care Research. That proposed program remains in planning and has not received protocol approval, so nobody should count it as a done deal.
- Can image-based indicators add useful information beyond established testing?
- How do sensitivity, specificity, and follow-up recommendations hold up in independent clinical studies?
- Will users and providers understand that a preliminary indicator is not a diagnosis?
- Can the company manage privacy, workflow, and reimbursement as it moves beyond research?
Commercial Traction Exists, but the Claims Need Room to Breathe
Faex reports four signed agreements representing about 150,000 covered lives, with its first 50,000 covered lives active as of November 2026. For a young digital-health platform, that is a real commercial foothold, not just a conference-slide aspiration. Still, covered lives are not the same as sustained engagement, clinical adoption, or durable revenue. Those are separate hurdles, and healthcare has buried plenty of clever products beneath procurement delays and proof demands.
The company is also researching stool-visible indicators for more than 100 additional conditions. Ambition is fine; sprawl is not. Expanding from 18 investigational conditions to a much larger universe may eventually strengthen the platform, but only if validation stays disciplined condition by condition. Ebola and H. pylori make for attention-grabbing additions. The investment-grade question is duller and much more important: can Faex generate independent clinical evidence showing that its alerts improve the path to appropriate testing without creating harmful noise?
For now, this looks like an intriguing monitoring concept with early commercial movement and a long clinical road ahead. The promise is accessible observation, especially in places with limited diagnostic infrastructure. The burden is proving that the observation is reliable enough to deserve action. In health technology, that burden is not bureaucratic clutter. It is the whole ballgame.